Alzheon Moves Forward With Tramiprosate Development in Select Alzheimer’s Patients

Alzheon Moves Forward With Tramiprosate Development in Select Alzheimer’s Patients
Data from Phase 3 trials of tramiprosate (ALZ-801) suggest that the therapy might be modifying the disease course in patients with mild Alzheimer’s disease and two copies of the APOE4 gene, the drug’s developer, Alzheon, recently announced. With data in hand, the Framingham, Massachusetts, company plans to further clinical development of the compound. But for now, Alzheon will use a precision medicine approach, including only patients with these characteristics in an additional Phase 3 trial. The findings, published in The Journal of the Prevention of Alzheimer’s Disease, showed that patients with mild Alzheimer’s experienced a stabilization of cognitive and functional capacities to a larger degree than a combined group of patients with both mild and moderately severe Alzheimer’s. The study, “Clinical Effects of Tramiprosate in APOE4/4 Homozygous Patients with Mild Alzheimer’s Disease Suggest Disease Modification Potential,” also suggested that effects on cognition increased significantly with time. “We are now seeing a convergence of new insights on how amyloid-targeted therapies can be optimized to treat Alzheimer’s disease patients,” Dr. Jeffrey Cummings, director of the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas, said in a
Subscribe or to access all post and page content.